greeksoup/ stock research

Veracyte (VCYT) Q1 FY2026 earnings: revenue $139 million, up 21.5% on the year

Veracyte, Inc. (VCYT) reported revenue of $139 million for Q1 FY2026, the quarter ended 31 March 2026, up 21.5% on the same quarter a year earlier. Net income was $29 million, up 307.4% on the year, and diluted earnings per share $0.35. The figures are the company's own, from the 10-Q it filed with the SEC on 6 May 2026.

Revenue$139 millionup 21.5%
Net income$29 millionup 307.4%
Diluted EPS$0.35
QuarterQ1 FY2026ended 31 March 2026

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue139141114+21.5%
Gross profit10110279.5+27.2%
Gross margin72.7%72.5%69.5%
Research and development27.120.817.7+52.9%
Operating income22.637.22.9+679.8%
Operating margin16.3%26.4%2.5%
Pre-tax income30.040.67.4+303.5%
Income tax1.3-0.50.4+232.5%
Effective tax rate4.2%-1.3%5.1%
Net income28.741.17.0+307.4%
Net margin20.6%29.3%6.2%
Diluted EPS$0.35$0.51$0.09+288.9%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow35.252.65.4+556.8%
Capital expenditure3.03.81.8+62.8%
Free cash flow32.348.83.5+810.3%
Free cash flow margin23.2%34.7%3.1%
Cash from investing-128-5.4-51.8n/a
Cash from financing-6.6-0.1-6.5n/a
Depreciation and amortisation5.45.35.4+1.3%
Share-based compensation12.810.911.0+16.5%
Diluted shares, weighted81m81m80m+1.6%
Shares outstanding at period end80m79m78m+1.9%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Shareholders' equity1,3441,3101,195+12.5%
Debt0.00.00.0n/a
Operating lease liabilities35.035.643.1-18.8%
Other liabilities57.060.877.4-26.3%
Total liabilities and equity1,4361,4061,315+9.2%
Goodwill767767754+1.7%
Intangible assets85.989.199.1-13.4%
Investmentsn/a50.3n/an/a
Securities held for sale or to maturity176n/a101+73.8%
Cash and equivalents263363186+41.4%
Receivables50.144.753.8-6.8%
Inventoryn/a20.524.3n/a
Other assets94.271.696.7-2.5%
Total assets1,4361,4061,315+9.2%

Questions

What was Veracyte's revenue in Q1 FY2026?

Veracyte (VCYT) reported revenue of $139 million for Q1 FY2026, the quarter ended 31 March 2026, up 21.5% on the same quarter a year earlier.

How much did Veracyte earn in Q1 FY2026?

Net income for Q1 FY2026 was $29 million, up 307.4% on the year, and diluted earnings per share $0.35.

When did Veracyte report Q1 FY2026 results?

Veracyte filed its 10-Q for the quarter ended 31 March 2026 with the SEC on 6 May 2026.

Quarterly results, the last 12 quarters

Q3 FY2023 †Q4 FY2023 *Q1 FY2024 †Q2 FY2024Q3 FY2024Q4 FY2024 * †Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue90.198.296.8114116119114130132141139150
Gross profit57.7n/a62.577.979.078.879.589.891.3102101109
Gross margin64%n/a65%68%68%66%69%69%69%73%73%72%
R&D13.318.716.016.517.619.317.716.316.020.827.129.4
Operating income-31.7-35.5-4.74.612.04.22.9-5.322.937.222.623.0
Operating margin-35%-36%-5%4%10%4%3%-4%17%26%16%15%
Pre-tax income-29.8-30.5-1.97.416.83.47.41.218.940.630.026.5
Tax raten/an/an/a22%10%-49%5%178%-1%-1%4%4%
Net income-29.6-28.3-1.95.715.25.17.0-1.019.141.128.725.5
Net margin-33%-29%-2%5%13%4%6%-1%15%29%21%17%
Diluted EPS-$0.41-$0.39-$0.02$0.07$0.19$0.07$0.09-$0.01$0.24$0.51$0.35$0.31
Operating cash flow14.215.6-9.029.630.024.55.433.644.852.635.245.8
Capital expenditure2.82.52.12.82.24.11.81.32.83.83.02.9
Free cash flow11.413.1-11.126.827.720.43.532.342.048.832.343.0
Shares outstanding73m73m76m77m77m78m78m79m79m79m80m80m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 31 March 2026, filed 6 May 2026, accession 0001384101-26-000031: the filing on EDGAR. All of Veracyte, Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install